BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...
BioCentury | Nov 11, 2019
Clinical News

DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Infectious disease; hepatic

INDICATION: Sepsis; liver disease Patient sample and mouse studies suggest inhibiting NMI could help treat sepsis and liver injury, and inhibiting IFI35 could help treat sepsis. In serum samples from sepsis patients, NMI levels were...
BioCentury | Aug 4, 2016
Product R&D

Antibiotic wisdom

While one of the biggest problems in infectious diseases is the overuse of antibiotics, few point-of-care tools are available to help physicians decide when and what to prescribe. Focusing on host genes rather than microbial...
BioCentury | Jul 23, 2015
Tools & Techniques

The price of a gold standard

While a new protocol for validating antibodies from the Structural Genomics Consortium goes part way toward addressing one of the biggest sources of irreproducibility in academic research, stakeholders agree a widespread solution will likely require...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...
BioCentury | Aug 7, 2014
Cover Story

Dyeing to diagnose preeclampsia

...amyloid precursor protein ( APP ); ceruloplasmin ferroxidase ( CP ); interferon-a inducible protein 6 (IFI6...
BioCentury | Dec 23, 2013
Company News

Imprimis pharmaceuticals news

Imprimis also said it discontinued a Phase III program for Impracor, a topical cream formulation of 10% ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), that uses Accudel technology. In August, Imprimis said it would delay the...
BioCentury | May 6, 2013
Finance

Sufficiently graft-ifying

Sufficiently graft-ifying Opsona Therapeutics Ltd. took the rare step of turning down money in last week's series C round, as the immunology company capped the financing at €33 million ($43 million) to avoid dilution. The...
Items per page:
1 - 10 of 13